Documentdetail
ID kaart

oai:HAL:hal-04051040v1

Onderwerp
Alzheimer's disease biomarker Electrochemical biosensor Molecularly imprinted polymer (MIP... Parkinson's disease biomarker [CHIM]Chemical Sciences
Auteur
Pilvenyte, Greta Ratautaite, Vilma Boguzaite, Raimonda Samukaite-Bubniene, Urte Plausinaitis, Deivis Ramanaviciene, Almira Bechelany, Mikhael Ramanavicius, Arunas
Langue
en
Editor

HAL CCSD;Elsevier

Categorie

Chemical Sciences

Jaar

2023

vermelding datum

07-12-2023

Trefwoorden
alzheimer diseases biomarker parkinson molecularly imprinted polymers disease biomarkers
Metriek

Beschrijving

International audience; The appearance of the biomarkers in body fluids like blood, urine, saliva, tears, etc. can be used for the identification of many diseases.

This article aimed to summarize the studies about electrochemical biosensors with molecularly imprinted polymers as sensitive and selective layers on the electrode to detect protein-based biomarkers of such neurodegenerative diseases as Alzheimer's disease, Parkinson's disease, and stress.

The main attention in this article is focused on the detection methods of amyloid-β oligomers and p-Tau which are representative biomarkers for Alzheimer's disease, α-synuclein as the biomarker of Parkinson's disease, and α-amylase and lysozyme as the biomarkers of stress using molecular imprinting technology.

The research methods, the application of different electrodes, the influence of the polymers, and the established detection limits are reviewed and compared

Pilvenyte, Greta,Ratautaite, Vilma,Boguzaite, Raimonda,Samukaite-Bubniene, Urte,Plausinaitis, Deivis,Ramanaviciene, Almira,Bechelany, Mikhael,Ramanavicius, Arunas, 2023, Molecularly imprinted polymers for the recognition of biomarkers of certain neurodegenerative diseases, HAL CCSD;Elsevier

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw